| Autor: |
Солодянникова, О. І., Шипко, А. Ф., Даниленко, В. В., Сукач, Г. Г. |
| Předmět: |
|
| Zdroj: |
Problems of Radiation Medicine & Radiobiology; 2022, Issue 27, p131-137, 7p |
| Abstrakt: |
The scope of scientific literature was reviewed to summarize the data on the 223Ra-dichloride therapy for castration& resistant forms of prostate cancer. Key advantages of the alpha-emitters over beta&emitting radionuclides are high-lighted in the treatment of hormone-resistant bone metastases. Data demonstrating an association between the 223Ra-dichloride treatment effectiveness and absorbed therapeutic doses were analyzed. Dependence between the 223Ra and 18F-fluoride absorbed doses in bone metastases was evaluated, which should be taken into account in a positron emission tomography monitoring. Results of studies examining the uptake of 18F-fluoride to predict the 223Ra-dichloride accumulation during the first course of treatment were analyzed. Research areas requiring further concern have been identified through the literature review, namely: study of the relationship between an absorbed dose and other clinically relevant endpoints, including pain index, changes in alkaline phosphatase or prostate anti& gen levels, survival rates, and development of alternative treatment regimens depending on the therapeutic radio& pharmaceutical dose. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
